WASHINGTON — Legislation targeting Chinese biotechnology companies caused a ruckus early this year. None of that may matter if Congress doesn’t pass it in December.
The BIOSECURE Act would restrict U.S. pharmaceutical and biotechnology companies from doing business with certain Chinese companies, including WuXi AppTec and WuXi Biologics. The bill would increase costs for drugmakers. The biopharma industry has come to rely heavily on those companies for contract manufacturing and other important services.
BIOSECURE has strong bipartisan support, as lawmakers look to signal that they’re tough on China, and it could be added to either must-pass defense budget legislation, which is viewed as the most likely vehicle, or a government-funding bill.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in